Kubota Pharmaceutical Holdings Co., Ltd. announced the database lock for the phase 3 clinical trial of the investigational visual cycle modulator emixustat hydrochloride (emixustat) in patients with Stargardt Disease. Kubota Vision previously announced that the trial was completed in June 2022, as the last patient underwent their last visit. This was followed by completion of data entry, confirmation of the accuracy and completeness of the database, and final sign-off by all investigators.

Now that the database is locked, the datasets are being transferred to an independent statistical group, who will unmask patient treatment and analyze the data. Top-line results will be reported by Kubota Vision in August 2022.